港股異動 | 聯邦制藥漲5% 抗感染藥物注射用哌拉西林鈉他唑巴坦鈉通過一致性評價
格隆匯6月13日丨聯邦制藥(3933.HK)漲5.15%,報4.29港元,總市值78億港元,六日累漲20.73%,股價創兩個月新高。聯邦制藥10日公佈,全資附屬珠海聯邦制藥申報的注射用哌拉西林鈉他唑巴坦鈉經中國國家藥品監督管理局審批,通過仿製藥質量和療效一致性評價。該產品為複方抗感染藥物,適用治療由肺炎、泌尿道感染、皮膚及軟組織感染等,為2021年版國家醫保目錄乙類藥品。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.